• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk

Eli Lilly, Express Scripts offer insulin discount program

December 14, 2016 By Sarah Faulkner

Eli Lilly

Eli Lilly (NYSE:LLY) said it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans. The program will begin January 1, 2017 and will cover Lilly’s insulins Humalog, Humulin, and the biologic Basaglar. Lilly said it anticipates the program […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: CVS Health, Eli Lilly & Co., Express Scripts, Novo Nordisk, Sanofi-Aventis

Novo Nordisk joins Allergan in pledge to limit price hikes

December 6, 2016 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) president Jakob Riis said this week that the company will limit annual price hikes of its products’ list prices to single-digit percentages, joining Allergan (NYSE:AGN) CEO Brent Saunders who released a “social contract” 3 months ago with the same goal. “We hear from more and more people living with diabetes about the challenges […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Mylan, Novo Nordisk

Nordisk touts Tresiba insulin injection data

November 30, 2016 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) said today that data from the Devote clinical trial indicated that its injected insulin, Tresiba, reduced the risk of severe hypoglycemia when compared to insulin glargine. The trial enrolled more than 7,500 type 2 diabetes patients at high risk of adverse cardiovascular events and treated them for 2 years with either Tresiba or insulin glargine […]

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Novo Nordisk

Novo Nordisk, Sanofi win FDA nods for diabetes drugs

November 22, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Both Novo Nordisk (NYSE:NVO) and Sanofi (NYSE:SNY) said yesterday that they won FDA approval for pre-filled pens with drug combinations indicated for adults with Type II diabetes. Paris-based Sanofi’s Soliqua 100/33 is an injectable medicine composed of 2 diabetes drugs – insulin glargine and lixisenatide. The drug is approved for adults with Type II diabetes not controlled with less than […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Novo Nordisk, Sanofi-Aventis

Novo Nordisk’s Fiasp wins EU nod; Danish firm plans emerging markets push

November 14, 2016 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) said today that the European Union’s Committee for Medicinal Products for Human Use issued a positive opinion on its fast-acting insulin analogue, Fiasp. The Danish company also committed to expanding its Changing Diabetes in Children program, which provides access to diabetes care and free insulin to children with Type I diabetes in developing countries. The […]

Filed Under: Diabetes, Featured, Regulatory/Compliance Tagged With: Novo Nordisk

Trump’s win boosts drug stocks

November 9, 2016 By Sarah Faulkner

Pharmaceutical stocks surged today after Donald Trump won the U.S. presidential election, as investors concluded the threat of action on drug pricing had lessened. California’s Proposition 61, which would have prevented the state of California from purchasing drugs from a manufacturer for a price higher than that paid by the U.S. Veterans Affairs Dept., failed to […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mylan, Novo Nordisk, Roche

Novo Nordisk shares dive after long-term growth cut

October 28, 2016 By Sarah Faulkner

Novo Nordisk

(Reuters) — Top insulin maker Novo Nordisk (NYSE:NVO) slashed its long-term profit growth forecast today, signaling no let-up in its struggles to crack the U.S. market to which its chief executive said its commitment would not waver. The Danish firm’s shares fell by as much as 19% to a 30-month low, wiping more than $15 billion off […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 6
  • Go to page 7
  • Go to page 8

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS